CVS to exit core infusions services business, job cuts possible
By Amina Niasse
NEW YORK, Oct 11 (Reuters) -CVS Health CVS.N is exiting its core infusion services business and plans to either close or sell 29 related regional pharmacies in the coming months, a company spokesperson confirmed to Reuters on Friday.
Details of the strategic shift were announced in a CVS corporate memo dated Oct. 8 and seen by Reuters.
The company on Oct. 8 stopped taking new patients seeking antibiotics, drugs supporting muscular health, and intravenous nutrition services, Shelly Bandit, a senior manager of corporate communications, told Reuters.
CVS bought Coram LLC, a drug infusion services provider, for $2.1 billion in 2013.
"Providers of infused medications have continued to face a challenging environment for their most highly specialized, complex services, and Coram has not been immune to these challenges," Bandit added.
It will continue to provide specialty medications and enteral nutrition, or tube feeding, at pharmacies in Minnesota, Pennsylvania and San Diego, and provide nursing services nationwide.
She said the company has not yet announced any workforce reductions and that any impacted employees would be notified in mid-November with the roles ending in January.
Patients still relying on the targeted therapies will be transferred to other infusion providers, Bandit said.
The move is not related to the company's plan to cut 2,900 corporate jobs.
"We plan to close 29 regional pharmacies over the coming months, but are also exploring a possible sale of these assets," Bandit said.
Reporting by Amina Niasse
Editing by Caroline Humer and Bill Berkrot
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
